Form 4: Mersana Therapeutics Director Dere Willard H. Acquires 55,000 Stock Options
SEC Form 4 Filing
Director Dere Willard H. acquired 55,000 stock options in Mersana Therapeutics, Inc. on June 11, 2024.
Summary
- On June 11, 2024, Dere Willard H., a director of Mersana Therapeutics, Inc., acquired 55,000 stock options.
- The options have an exercise price of $2.26.
- The options vest on the earlier of June 11, 2025, or the date of the 2025 Annual Meeting of Stockholders, contingent upon continuous service with the issuer.
- The expiration date for these options is June 10, 2034.
- Following the transaction, Dere Willard H. directly owns 55,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock option grants, which is a neutral event.
Industry Context
This filing reflects standard executive compensation practices within the biotechnology industry, where stock options are commonly used to incentivize and align the interests of directors and management with those of shareholders.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/11/2024 | Date of transaction: Dere Willard H. acquired 55,000 stock options. |
| 06/11/2025 | Earliest vesting date for the stock options, contingent upon continuous service. |
| 06/10/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.